Sequana Medical
Sequana Medical develops the alfapump® system for treating drug-resistant fluid overload in liver disease, heart failure, and cancer.
Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer. The company's alfapump® system is approved in Europe but not yet in Canada for commercial use. DSR® therapy is in development and not yet approved in the United States or Canada.
Stated facts & numbers
- Sequana Medical IPO'd on the Brussels exchange in February 2019 at around €8.5 and has now filed for bankruptcy after failed commercialization despite FDA approval. (0:02:36, De Tijd 2026-07-01)